Adimab, LLC on January 14, 2020, announced that it has extended its Adimab Platform license agreement with Novo Nordisk for the discovery and optimization of antibody-based protein therapeutics. This agreement extends an ongoing partnership between the two companies that began in 2013. Under the terms of the agreement, Novo Nordisk will have continued access to a unique human antibody library and will receive a license to the Adimab Platform for use on an unlimited number of targets. Novo Nordisk also has the ability to access improvements to the Adimab Platform, including new antibody libraries, software upgrades, and novel protein engineering capabilities. Adimab will receive an undisclosed extension fee as well as development and sales milestones plus tiered royalties on the annual net sales.